Study Title
ANZUP 1302: Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
Protocol ID
ANZUP 1302
Condition/s
Germ Cell Tumour
Diagnosis Stage
New diagnosis
Location
NSW, QLD, NZ
Sponsor
University of Sydney
Collaborators
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Cambridge University Hospitals NHS Foundation Trust
Cancer Trials Ireland
Children's Oncology Group
Dana-Farber Cancer Institute
University of Southern California
Cambridge University Hospitals NHS Foundation Trust
Cancer Trials Ireland
Children's Oncology Group
Dana-Farber Cancer Institute
University of Southern California
Links
Trial Status
Open
Sites
Queensland Children's Hospital
Starship Hospital
John Hunter Children's Hospital
Starship Hospital
John Hunter Children's Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
11 Years to 45 Years
International registry ID's
NCT02582697
| Study Title | ANZUP 1302: Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours |
|---|---|
| Protocol ID | ANZUP 1302 |
| Disease (Sub Disease) | Germ Cell Tumour |
| Diagnosis Stage | New diagnosis |
| Location | NSW / QLD / NZ |
| Sponsor | University of Sydney |
| Collaborators | Australian and New Zealand Urogenital and Prostate Cancer Trials Group/ Cambridge University Hospitals NHS Foundation Trust/ Cancer Trials Ireland / Children's Oncology Group/ Dana-Farber Cancer Institute/ University of Southern California |
| Links | https://clinicaltrials.gov/ct2/show/NCT02582697 |
| Trial Status | Open |
| Trial Open Date | 01/02/2014 |
| Sites | Queensland Children's Hospital / Starship Hospital/ John Hunter Children's Hospital/ |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | 11 Years to 45 Years |
| International registry ID's | NCT02582697 |